Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page
   

NIDA Home > Publications > Director's Reports > February, 2010 Index    

Director's Report to the National Advisory Council on Drug Abuse - February, 2010



Program Activities

New NIDA PAs and RFAs

On November 4, 2009, NIDA issued a PA entitled Drug Abuse Dissertation Research: Epidemiology, Prevention, Treatment, Services, and/or Women and Sex/Gender Differences (R36) PAR-10-020. This FOA will utilize the NIH Dissertation Award (R36) grant mechanism.

On November 5, 2009, NIDA issued AIDS-Science Track Award for Research Transition (R03) PAR-10-021. This FOA seeks to facilitate the entry of both newly independent and early career investigators to the area of drug abuse research on HIV/AIDS. This FOA, AIDS--Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug abuse and HIV/AIDS that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

On January 4, 2010, NIDA issued Mechanism for Time-Sensitive Drug Abuse Research (R01) PAR-10-072. This is intended to support substance abuse prevention and treatment services research in rapidly evolving areas (e.g., changes in service systems, health care financing, policy, natural/man-made disasters, etc) where opportunities for empirical study are, by their very nature, only available through expedited review and award of support. There are three distinguishing features of an eligible study: 1) the study's scientific value and feasibility are clear, 2) rapid review and funding are required in order for the scientific question to be answered, and 3) the knowledge gained from the study is time-sensitive and seeking funding through the regular NIH cycle of review and award would result in a missed opportunity to conduct the research. It should be clear that the research question offers an uncommon and scientifically significant research opportunity that could only become available if the project is initiated with minimum delay. Opening Date: February 9, 2010 (Earliest date an application may be submitted to Grants.gov); Letters of Intent Receipt Date(s): 4 weeks prior to planned submission date: Application Submission/Receipt Date(s): March 9, 2010, June 9, 2010, September 10, 2010 December 9, 2010, March 9, 2011, June 9, 2011, September 9, 2011, December 9, 2011, March 9, 2012, June 8, 2012, September 10, 2012, December 10, 2012.

On September 3, 2009, NIDA issued RFAs entitled Exploring Epigenomic Processes and Non-Coding RNAs in HIV/AIDS (R01) RFA-DA-10-010 and (R21) RFA-DA-10-011. The purpose of these FOAs is to enhance our understanding of the role of epigenomics in HIV infection and pathogenesis in combination with substance abuse. They invite applications proposing innovative research to stimulate new areas of research or develop new approaches to existing studies. Newly-formed collaborations to foster sharing of expertise between the fields of HIV/AIDS, drug abuse, and epigenomics research are encouraged. Letters of Intent Receipt Date(s) for this FOA: November 23, 2009; Application Due Date(s): December 23, 2009.

On September 17, 2009, NIDA issued an RFA entitled Targeted Library Synthesis and Screening at Novel Targets for Potential Drug Addiction Treatments and Research Tools (R21/R33) RFA-DA-10-005. This FOA solicits research applications from institutions/organizations that propose to promote the discovery of novel medications through the use of targeted library synthesis and screening for drug addiction treatment, as well as the discovery of CNS-active research tools for medication target validation in animal models of drug addiction. Letters of Intent Receipt Date(s): November 4, 2009; Application Due Date(s): December 4, 2009.

On September 24, 2009, NIDA issued an RFA entitled Medications Development for Cannabis-Related Disorders (R01) RFA-DA-10-016. The purpose of this FOA is to support research studies that focus on the identification, and preclinical and clinical evaluation, of medications that can be safe and effective for the treatment of cannabis-use and -induced disorders, as well as their medical and psychiatric consequences. The studies can be preclinical or FDA-defined Phase I, Phase II or Phase III clinical trials. Letters of Intent Receipt Date(s): March 30, 2010; Application Due Date(s): April 30, 2010.

On December 9, 2009, NIDA issued Cognitive Remediation Approaches to Improve Drug Abuse Treatment Outcomes (R01) RFA-DA-10-006 and (R21) RFA-DA-10-007. There is a significant public health need to improve the outcome of treatments of substance use disorders (SUDs). SUDs are often associated with cognitive changes that may negatively impact drug abuse treatment outcomes. The purpose of these FOAs is to solicit clinical research project applications that design and/or develop cognitive remediation strategies that enhance the outcome of SUD treatments. Letters of Intent Receipt Date(s): March 8, 2010; Application Due Date(s): April 7, 2010.

On December 18, 2009, NIDA issued the 2010 NIDA Avant-Garde Award Program for HIV/ AIDS Research (DP1) RFA-DA-10-012. The NIDA Avant-Garde Award Program for HIV/AIDS Research is meant to complement NIDA's traditional investigator-initiated grant programs by supporting individual scientists of exceptional creativity who propose high-impact research that will open new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term "avant-garde" is used to describe highly innovative approaches that have the potential to be transformativeÑopen new areas of research or lead to new avenues of treatment and prevention for HIV/AIDS among drug abusers. The proposed research should reflect ideas substantially different from those already being pursued by the investigator or others. The 2010 Avant-Garde Award competition will proceed in two phases. The first phase is a pre-application phase in response to PAR-10-068. Pre-applications will be evaluated by a group of external reviewers. Those investigators whose submissions are judged to be the most outstanding will be notified of the opportunity to submit full applications under this FOA (DP1). The 2010 Avant-Garde awardees will be selected from this group of applicants. Application Due Date(s): June 2, 2010.

PAs/RFAs Issued with Other NIH Components/Agencies

On October 14, 2009, NIDA, in collaboration with NIAAA, issued PAs entitled Behavioral & Integrative Treatment Development Program (R03) PA-10-011 and (R34) PA-10-013. The purpose of these FOAs is to encourage early career investigators or investigators who are striving to make a shift in their research to propose discrete, well-defined projects that can be completed within two years with limited resources. Projects of interest fall within the research domain of behavioral, combined, sequential, or integrated (behavioral/pharmacological) (1) drug abuse treatment interventions, including interventions for patients with comorbidities, in diverse settings; (2) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (3) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (4) interventions to treat chronic pain. Specific examples include: 1) Stage I pilot or feasibility studies; 2) secondary analysis of existing data; 3) small, self-contained research projects; 4) development of research assessments or methodology; and 5) development of new research technology.

On October 14, 2009, NIDA, in collaboration with NIAAA and NINR, issued the PA entitled Behavioral & Integrative Treatment Development Program (R01) PA-10-012. The purpose of this FOA for R01 applications is to encourage Stage II or Stage III research to conduct clinical trials, examine mechanisms of behavior change, determine dose-response, optimize combinations, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological (1) drug abuse treatment interventions, including interventions for patients with comorbidities, in diverse settings; (2) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (3) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (4) interventions to treat chronic pain.

On October 30, 2009, NIDA, in collaboration with NCI and OBSSR, issued the PA entitled Accelerating the Pace of Drug Abuse Research Using Existing Epidemiology, Prevention, and Treatment Research Data (R01) PAR-10-018. This FOA invites applications to support the innovative analysis of existing social science and behavioral data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, and other drug), HIV risk behaviors, related disorders, prevention and treatment of these behaviors, and health service utilization including quality, access, and costs. NIDA and NCI encourage coordinated analyses of substance abuse research data that are in public use or that are privately held by a principal investigator.

On November 16, 2009, NIDA, in collaboration with NCI and NHLBI, issued Effectiveness Research on Smoking Cessation in Hospitalized Patients (U01) RFA-HL-10-020. This FOA solicits Cooperative Agreement (U01) applications from institutions/organizations that propose to study the effectiveness of smoking cessation interventions for hospitalized patients. Hospitalization provides a unique opportunity for smoking cessation, and although the nature of cessation interventions during hospitalization varies widely, these interventions appear efficacious when continued cessation support is provided for at least one month post-discharge. Therefore, the purpose of this FOA is to encourage research to evaluate the translation of efficacious smoking cessation strategies initiated during hospitalization and continued post-discharge into effective programs that can be widely implemented in routine clinical practice and assess the cost-effectiveness of these interventions. Letters of Intent Receipt Date: December 18, 2009; Application Due Date: January 19, 2010.

On November 20, 2009, NIDA, in collaboration with NIMH, NIA, NIAAA and NIBIB, issued Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) PA-10-023. This FOA invites research grant applications from organizations/institutions that propose the development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.

On November 20, 2009, NIDA, in collaboration with NIMH, NIA, and NIAAA, issued Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (Phased Innovation Award [R21/R33]) PAR-10-024. This FOA invites research grant applications from organizations/ institutions that propose the development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.

On November 24, 2009, NIDA, in collaboration with NIMH and NIAID, issued Seek, Test, and Treat: Addressing HIV in the Criminal Justice System (R01) RFA-DA-10-017. This initiative solicits R01 applications to empirically test the seek, test, and treat paradigm in criminal justice populations. The seek, test, and treat model involves reaching out to high risk, hard to reach groups who have not been recently tested (seek), engaging them in HIV testing (test), and initiating, monitoring, and maintaining HAART for those testing positive (treat). Researchers are encouraged to develop, implement, and test strategies to increase HIV testing and the provision of HAART to HIV seropositive individuals involved with the criminal justice system, with particular focus on continuity of HAART during and after community re-entry following incarceration. Key outcome measures include linkage to care (e.g., seen at care center post-release) and viral suppression (e.g., proportion with undetectable viral load 6 months or more after initiation of ART). Applications responsive to this FOA may propose intervention research at the individual, organizational, or system level that leads to effective approaches for expanding access to HIV testing and HAART treatment in the criminal justice system and in community organizations working with criminal justice systems and populations. Letters of Intent Receipt Date(s): March 2, 2010; Application Due Date(s): April 1, 2010.

On December 4, 2009, NIDA and NIAAA issued Support Opportunity for Addiction Research (SOAR) for New Investigators (R03) RFA-DA-10-015. This FOA solicits applications to supplement new investigators who have, or have a commitment of support to conduct research in basic or clinical alcohol or drug abuse research from funding sources other than NIH (e.g. private foundation). In addition, those applicants currently supported to conduct research on psychiatric disorders that are often found to be co-morbid with substance abuse, are also eligible to apply to SOAR for the purpose of adding a substance or alcohol abuse research component to their on-going research. It is hoped that the SOAR program will facilitate ongoing supported substance abuse and co-morbidity research among entry-level new investigators. This FOA is intended to support new investigators' on-going basic or clinical alcohol, drug abuse and/or related co-morbidity research. The primary goal of this Support Opportunity for Addiction Research (SOAR) is for new investigators to leverage existing research programs in order to strengthen, possibly expand, and/or further develop alcohol, drug abuse, and co-morbidity research.Letters of Intent Receipt Date(s): March 16, 2010; Application Due Date(s): April 16, 2010.

On January 29, 2010 NIDA, in collaboration with NIMH and NICHD, issued Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) [U01] RFA-HD-10-015. The purpose of this FOA is to invite applications from investigators willing to participate with NICHD, NIDA, and NIMH under a cooperative agreement to support the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN). The primary mission of the ATN will be to conduct research, both independently and in collaboration with existing research networks and individual investigators, in HIV-infected and HIV-at-risk pre-adolescents, adolescents, and young adults up to age 25 years. This network will have the capacity for developing and conducting selected behavioral, community-based translational, prophylactic, therapeutic, microbicide and vaccine trials. Letters of Intent Receipt Date(s): March 14, 2010; Application Receipt Dates(s):April 14, 2010.

Additional PAs/RFAs Issued with Numerous Other NIH/HHS Components

Limited Competition for the Pediatric HIV/AIDS Cohort Study (U01) RFA-HD-09-006. Application Receipt Date: October 28, 2009

Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA) (R01) RFA-GM-10-009. Application Due Date(s): November 24, 2009

Recovery Act Limited Competition: Building Sustainable Community-Linked Infrastructure to Enable Health Science Research (RC4) RFA-OD-09-010. Letters of Intent Receipt Date(s): November 12, 2009; Application Due Date(s): December 11, 2009

NIH Blueprint for Neuroscience Research Competitive Revisions for Studies Focused on Neuropathic Pain or Neural Plasticity to Promote Collaborative Pain Research (R01) PAR-09-264. Application Due Date(s): November 23, 2009

Bioengineering Nanotechnology Initiative (STTR [R41/R42]) PA-09-266

Bioengineering Nanotechnology Initiative (SBIR [R43/R44]) PA-09-267

Drug Discovery for Nervous System Disorders (R01) PAR-10-001

Drug Discovery for Nervous System Disorders (R21) PAR-10-002

Mechanisms, Models, Measurement, & Management in Pain Research (R01) PA-10-006

Mechanisms, Models, Measurement, & Management in Pain Research (R21) PA-10-007

Mechanisms, Models, Measurement, & Management in Pain Research (R03) PA-10-008

Bioengineering Research Grants (BRG) (R01) PA-10-009

Exploratory/Developmental Bioengineering Research Grants (EBRG) [R21] PA-10-010

Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) PA-10-036

Ruth L. Kirschstein National Research Service Award Short-Term Institutional Research Training Grants (T35) PA-10-037

Blueprint Program for Enhancing Neuroscience Diversity through Undergraduate Research Education Experiences (R25) RFA-MH-10-070. Letters of Intent Receipt Date(s): February 24, 2010; Application Submission/Receipt Date(s): March 24, 2010

Dissemination and Implementation Research in Health (R01) PAR-10-038

Dissemination and Implementation Research in Health (R03) PAR-10-039

Dissemination and Implementation Research in Health (R21) PAR-10-040

Mentored Research Scientist Development Award (Parent K01) PA-10-056

Independent Scientist Award (Parent K02) PA-10-057

Mentored Clinical Scientist Research Career Development Award (Parent K08) PA-10-059

Mentored Patient-Oriented Research Career Development Award (Parent K23) PA-10-060

Midcareer Investigator Award in Patient-Oriented Research (Parent K24) PA-10-061

Mentored Quantitative Research Development Award (Parent K25) PA-10-062

NIH Pathway to Independence Award (Parent K99/R00) PA-10-063

NIH Small Research Grant Program (Parent R03) PA-10-064

Research Project Grant (Parent R01) PA-10-067

NIH Exploratory Developmental Research Grant Program (Parent R21) PA-10-069

Academic Research Enhancement Award (Parent R15) PA-10-070

ARRAOS: Recovery Act Limited Competition: Behavioral Economics for Nudging the Implementation of Comparative Effectiveness Research: Clinical Trials (RC4) RFA-OD-10-001

ARRAOS: Recovery Act Limited Competition: Behavioral Economics for Nudging the Implementation of Comparative Effectiveness Research: Pilot Research (RC4) RFA-OD-10-002

Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4) RFA-OD-10-005

Recovery Act Limited Competition: NIH Basic Behavioral and Social Science Opportunity Network (OppNet) Short-term Mentored Career Development Awards in the Basic Behavioral and Social Sciences for Mid-career and Senior Investigators (K18) RFA-OD-10-003

NIH Support for Conferences and Scientific Meetings (Parent R13/U13) PA-10-071

Recovery Act Limited Competition: Institutional Comparative Effectiveness Research Mentored Career Development Award (KM1) RFA-OD-10-011. Opening Date: February 25, 2010; Application Due Date: March 25, 2010

PHS 2010-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) PA-10-050

PHS 2010-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]) PA-10-051

Other Program Activities

Clinical Trials Network (CTN) Update

Protocols: A total of 43 protocols have been initiated since 2001, including multi-site clinical trials (29), multi-site surveys (3), studies in special populations (5), and secondary analyses of data across various trials (6). In addition, 18 ancillary studies have been supported by CTN and non-CTN funds. Over 11,000 participants have enrolled in CTN studies.

Primary outcome papers are published and dissemination materials have been developed with CSAT's ATTC on the following:

  • Protocol CTN 0001, Buprenorphine/Naloxone versus Clonidine for Inpatient Opiate Detoxification
  • Protocol CTN 0002, Buprenorphine/Naloxone versus Clonidine for Outpatient Opiate Detoxification
  • Protocol CTN 0005, MI (Motivational Interviewing) To Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse
  • Protocol CTN 0006, Motivational Incentives for Enhanced Drug Abuse Recovery: Drug Free Clinics
  • Protocol CTN 0007, Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics

Primary outcome papers are published or in press for:

  • Protocol CTN 0003, Bup/Nx: Comparison of Two Taper Schedules
  • Protocol CTN 0004, MET (Motivational Enhancement Treatment) To Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse
  • Protocol CTN 0008, A Baseline for Investigating Diffusion of Innovation
  • Protocol CTN 0009, Smoking Cessation Treatment with Transdermal Nicotine Replacement Therapy in Substance Abuse Rehabilitation Programs
  • Protocol CTN 0010, Buprenorphine/Naloxone-Facilitated Rehabilitation for Heroin Addicted Adolescents/Young Adults
  • Protocol CTN 0011, A Feasibility Study of a Telephone Enhancement Procedure (TELE) to Improve Participation in Continuing Care Activities
  • Protocol CTN 0012, Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infection, and Sexually Transmitted Infections in Substance Abuse Treatment Programs
  • Protocol CTN 0013, Motivational Enhancement Therapy to Improve Treatment Utilization and Outcome In Pregnant Substance Abusers
  • Protocol CTN 0015, Women's Treatment for Trauma and Substance Use Disorder: A Randomized Clinical Trial
  • Protocol CTN 0016, Patient Feedback: A Performance Improvement Study in Outpatient Addiction Treatment
  • Protocol CTN 0018, Reducing HIV/STD Risk Behaviors: A Research Study for Men in Drug Abuse Treatment
  • Protocol CTN 0019, Reducing HIV/STD Risk Behaviors: A Research Study for Women in Drug Abuse Treatment
  • Protocol CTN 0021, Motivational Enhancement Treatment to Improve Treatment Engagement and Outcome for Spanish-Speaking Individuals Seeking Treatment for Substance Abuse. This is the first Spanish-only protocol in the CTN.
  • Protocol CTN 0029, A Pilot Study of Osmotic-Release Methylphenidate (OROS MPH) in Initiating and Maintaining Abstinence in Smokers with ADHD.

In addition, the following protocols have submitted primary paper:

  • Protocol CTN 0017, HIV and HCV Intervention in Drug Treatment Settings
  • Protocol CTN 0030A2, Effects of Chronic Opioids in Subjects with a History of Opioid Use

The following protocols have locked the data:

  • Protocol CTN 0014, Brief Strategic Family Therapy for Adolescent Drug Abusers (BSFT)
  • Protocol CTN 0028, Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents with Substance Use Disorders (SUD).
  • Protocol CTN 0030, Prescription Opioid Addiction Treatment Study (POATS) is a randomized 2-phase, open-label, multi-center study in outpatient treatment settings. Pre-screening began in May 2006. The study, carried out in 9 sites, has randomized 653 participants into phase 1 and 360 participants into phase 2 and is currently in the close-out phase.
  • Protocol CTN 0030A1, Collection of Economic Data for the Prescription Opioid Addiction Treatment Study. This ancillary study was conducted in collaboration with NIDA DESPR and it is in the data analysis phase.

The following protocols has ended new enrollment, and are in the follow-up or data-lock phase:

  • Protocol CTN 0027, Starting Treatment with Agonist Replacement Therapies (START) is a randomized, open-label, multi-center study that was developed in collaboration with the Division of Pharmacotherapies & Medical Consequences of Drug Abuse (DPMCDA). 1,269 participants were randomized. Data collection is expected to end in June, 2010.
  • Protocol CTN 0027A1, START Pharmacogenetics: Exploratory Genetic Studies In Starting Treatment With Agonist Replacement Therapies. This ancillary study consented 843 of the 1,269 subjects from the START study. Data collection is expected to end in June, 2010.
  • Protocol CTN 0030A3, POATS Long-Term Follow Up Study (LTFU) is being conducted at all POATS sites to examine long-term outcomes for individuals who participated in CTN-0030 with opioid analgesic (OA) dependence. This study will follow POATS participants for 42 months after randomization in the POATS study.
  • Protocol CTN 0031, Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement. Recruitment was completed on September 30, 2009, yielding a total of 471 randomized participants across 10 sites. This total represents 21 more participants than proposed and was reached one week earlier than planned.
  • Protocol CTN 0031A1, An Evaluation of Neurocognitive Function, Oxidative Damage, and Their Association with Treatment Outcomes in Methamphetamine and Cocaine Abusers. Recruitment was completed on September 30, 2009, yielding a total of 173 participants across 6 sites who completed the data collection and blood draw procedures.
  • Protocol CTN 0031A2, The Role of Alcohol Consumption in Classifications of Alcohol Use Disorders: A Clinical Study. In collaboration with DESPR. The baseline data obtained in this research formed the foundation for an R01 grant awarded to Joseph Guydish, PhD, at the University of California, San Francisco.
  • Protocol CTN 0032, HIV Rapid Testing and Counseling in Drug Abuse Treatment Programs in the U.S. This study seeks to evaluate the most effective strategy to ensure that persons in drug treatment programs are tested for HIV and receive their HIV test results. The protocol has completed enrollment and is currently collecting the 6-month follow-up data. Twelve hundred and eighty one patients in 12 CTN community drug abuse centers were enrolled in 5 months.
  • Protocol CTN 0032A1, Economic Analysis of HIV Rapid Testing in Drug Abuse Treatment Programs. This ancillary study is an assessment of the cost-effectiveness of on-site HIV testing in drug abuse treatment settings vs. referral for off-site testing. The PI is Dr. Bruce Schackman. The project is conducted in collaboration with NIDA's DESPR.
  • Protocol CTN 0034-Ot, Developing Research Capacity and Culturally Appropriate Research Methods: Community-based Participatory Research Manual for Collaborative Research in Drug Abuse for American Indians and Alaska Natives. This study is in collaboration with the NIH National Center for Minority Health and Health Disparities and will be conducted in the Pacific Northwest Node.
  • Protocol CTN 0035-Ot, Access to HIV and Hepatitis Screening and Care among Ethnic Minority Drug Users In and Out of Drug Treatment. This study is in collaboration with the NIH National Center for Minority Health and Health Disparities and is being conducted in the California/Arizona Node.
  • Protocol CTN 0036-Ot, Epidemiology and Ethnographic Survey of "Cheese" Heroin Use among Hispanics in Dallas County. This study is in collaboration with the NIH National Center for Minority Health and Health Disparities and is being conducted in the Texas Node.

The following protocols are currently enrolling:

  • CTN-0027A2, Retention of Suboxone Patients in START: Perspectives of Providers and Patients. The overall purposes of the supplemental study are to identify and assess barriers for retaining Suboxone patients. This ancillary study is in the development phase.
  • Protocol CTN 0033-Ot, Methamphetamine Use among American Indians. The first area of research emphasis in the National Institute on Drug Abuse's Strategic Plan on Reducing Health Disparities (2004 Revision) is the epidemiology of drug abuse, health consequences and infectious diseases among minority populations. The study is a collaboration among four Nodes: Pacific NW, Southwest, Oregon/Hawaii, and Ohio Valley.

The following protocols are in the development phase:

  • Protocol CTN 0037, Exercise as a Treatment for Substance Use Disorders. This clinical trial will test the effectiveness of the addition of exercise in improving drug abuse treatment outcomes.
  • Protocol CTN-0038-Ot, Barriers to Substance Abuse Treatment among Asian Americans and Pacific Islanders. The objective of this study is to gain a better understanding of the factors that may influence the under-utilization of substance abuse treatment services by Asian Americans and Pacific Islanders (AAPIs) and the readiness of substance abuse treatment programs serving AAPIs to participate in clinical trials and adopt evidence based practices. This study is a collaboration with NIH NCMHD.
  • Protocol CTN 0044, Web-delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders. The purpose of this study is to evaluate the effectiveness of adding an interactive, web-based version of the Community Reinforcement Approach (CRA) intervention plus abstinence incentives as an adjunct to community-based, outpatient substance abuse treatment.
  • Protocol CTN 0045-Ot,Rates of HIV Testing and Barriers to Testing in African Americans Receiving Substance Abuse Treatment. This is an observational study seeking to: (1) Compare the proportion of African American and non-African Americans receiving treatment at substance abuse treatment clinics that have been tested for HIV within the past 12 months; (2) Observe relationships between rates of African Americans who have not been tested and a) the types of testing offered at substance abuse treatment clinics and b) the types of outreach strategies used to engage persons in HIV testing; and (3) assess African American clients' self-reported barriers to accessing HIV testing, in relation to other ethnicities.
  • Protocol CTN-0046, Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes. The primary objective of this study is to evaluate the impact of substance abuse treatment as usual plus smoking cessation treatment (TAU+SCT), relative to substance abuse treatment as usual (TAU), on drug abuse outcomes.
  • Protocol CTN-0047, Screening, Motivational Assessment, Referral and Treatment in Emergency Departments (SMART-ED). The study objective is to evaluate the implementation of and outcomes associated with a screening and brief intervention (SBI) process to identify individuals with substance use, abuse, or dependence seen in emergency departments (EDs) and to provide interventions and/or referral to treatment consistent with the severity of their substance use disorder.
  • Protocol CTN-0048, Screening, Motivational Assessment, Referral and Treatment in Dental Clinics. This concept is currently being developed into a protocol, in collaboration with the NIDCR and their clinical networks.

In addition to the primary CTN trials, there are currently five secondary analyses using data across several of the completed trials:

  1. Gender Differences in the Prevalence and Predictors of HIV Risk Behaviors, PI: Audrey Brooks (CA/AZ Node);
  2. Pattern of alcohol use and alcohol-related diagnoses among drug abusing/dependent participants, PIs: Dennis Donovan and Bryan Hartzler (Pacific Northwest Node);
  3. The relationships between demographic characteristics of patients and therapists, measures of therapeutic process and therapeutic alliance, and outcomes, PIs: Alyssa Forcehimes (Southwest Node) and Kathleen Burlew (Ohio Valley Node);
  4. The Efficacy of Motivational Enhancement Therapy for African Americans, PI: Kathleen Burlew (Ohio Valley Node);
  5. Substance Abuse Treatment Outcomes in Racial/Ethnic Minority Populations, PI: Carmen Masson (California-Arizona Node).

There are also about 40 funded studies supported by independent grants that use CTN studies as a platform.




NIDA's New and Competing Continuation Grants Awarded Since September 2009

Abood, Mary E. -- Temple University
Pamoic Acid Analogues as Potent GPR35 Agonists Inducing Antinociception

Ananthan, Subramaniam -- Southern Research Institute
Development of Dopamine D3 Ligands as Medications for Psychostimulant Addiction

Andersen, Susan L. -- McLean Hospital (Belmont, MA)
Early Drug Exposure and Drug Reward Mechanisms

Andrews, Judy A. -- Oregon Research Institute
Salivary Biomarkers (DNA, RNA and Cortisol), Life Stress and Nicotine Dependence

Anokhin, Andrey P. -- Washington University
Neurocognitive Effects of Nicotine Deprivation and Dopamine Genes

Anokhin, Andrey P. -- Washington University
Neurocognitive Predictors of Smoking Cessation

Arria, Amelia M. -- Treatment Research Institute, Inc. (TRI)
Internet as Supplier: Preventing Adolescent Use of Non-Medical Addictive Rx

Ball, Kevin -- Bloomsburg University of Pennsylvania
Neural Mechanisms Underlying Individual Differences in 3,4-Methylenedioxymethamphetamine

Barry, Colleen L. -- Yale University
Expanding Treatment of Opioid Dependence among the Privately Insured

Barth, Alison L. -- Carnegie-Mellon University
Development of a Fos-Channel Rhodopsin Transgenic Mouse

Beech, Robert David -- Yale University
Progesterone-Induced Gene Expression Changes and Risk of Relapse to Cocaine Use

Biglan, Anthony -- Oregon Research Institute
Creating the Scientific Infrastructure for the Promise Neighborhood Initiative

Blakely, Randy D. -- Vanderbilt University
Forward Genetics and the Presynaptic Dopamine Transporter

Blankenship, Kim M. -- Duke University
Drug Policy, Incarceration, Community Re-entry, and Race Disparities in HIV/AIDS

Boeri, Miriam W. -- Kennesaw State University
Methamphetamine Use in the Suburbs: An Exploratory Study

Bohn, Laura M. -- Scripps Research Institute
Physiological Implications of Serotonin Receptor Regulation

Bolton, Philip H. -- Wesleyan University
Finding Small Molecules that Modulate Gene Expression

Boyer, Edward W. -- University of Massachusetts Medical School, Worcester
A Mobile Enabling Technology to Promote Adherence to Behavioral Therapy

Bradberry, Charles W. -- University of Pittsburgh at Pittsburgh
Cognitive Dysfunction and Impaired Inhibitory Control in Cocaine Dependence

Breiter, Hans C. -- Massachusetts General Hospital
Imaging of DLPFC and Amygdala Impact on Relative Preference in Cocaine Addiction

Brooks, Adam C. -- Treatment Research Institute, Inc. (TRI)
Evaluation of Web-based Recovery Monitoring with Clinical Alerts

Buch, Shilpa J. -- University of Nebraska Medical Center
Cocaine & HIV: Role of PDGF/PDGF-Receptor Axis in Blood Brain Barrier Disruption

Buckner, Jane Hoyt -- Benaroya Research Institute at Virginia Mason
Linking Genetic Variation in the PTPN2 Gene to Autoimmune Disease Susceptibility

Bush, Terry -- Free and Clear, Inc.
Developing Behavioral Treatment Approaches for Obese Tobacco Quit Line Users

Carelli, Regina M. -- University of North Carolina Chapel Hill
Combined Voltammetry/Electrophysiology in Behaving Rats

Chen, Benjamin K. -- Mount Sinai School of Medicine of NYU
Imaging Virological Synapses During Parenteral HIV Transmission

Chen, Chi -- University of Minnesota Twin Cities
Metabolomic Investigation of Biosignatures of Chronic Cocaine Exposure

Chen, Xiangning -- Virginia Commonwealth University
Variants in Nicotine Receptors and Pharmacogenetics

Chen, Xiangning -- Virginia Commonwealth University
Variants in CHRNA5/CHRNA3/CHRNB4 and Nicotine Dependence

Cherner, Mariana -- University of California, San Diego
Genetics of Monooxygenase Activity & Methamphetamine-Related Brain Injury in HIV

Clarke, William P. -- University of Texas Health Sciences Center, San Antonio
Regulation of Opioid Receptor Function in Trigeminal Ganglion

Coatsworth, J. Douglas -- Pennsylvania State University-University Park
Efficacy Trial of a Mindfulness-Enhanced Strengthening Families Program

Collins, R. Lorraine -- State University of New York at Buffalo
Applying Behavioral Economics and EMA to Physical Activity and Marijuana Use

Colon, Vivian -- University of Puerto Rico Medical Sciences
HPV Infection among High-Risk Young Men in Puerto Rico

Compton, Margaret Ann -- University of California Los Angeles
Pain, Opioids and Pro-Inflammatory Immune Responses

Cottler, Linda B. -- Washington University
Transformative Approach to Reduce Research Disparities towards Drug Users

Cravatt, Benjamin F. -- Scripps Research Institute
A Quantitative Proteomics Platform to Characterize the Nicotine-Dependent Brain

Crystal, Ronald G. -- Weill Medical College of Cornell University
Adenovirus-based Anti-Cocaine Vaccine

Davis, Thomas Paul -- University of Arizona
Blood-to-CNS Drug Uptake in Pain

Dawson-Rose, Carol S. -- University of California, San Francisco
Impact of a Computer-Assisted SBIRT Program in an HIV Care Setting

De Felice, Louis J. -- Virginia Commonwealth University
Amphetamine Acts as a Molecular Stent in the Dopamine Transporter

De La Garza, Richard -- Baylor College of Medicine
RTI-336 as a Treatment for Methamphetamine Dependence

De La Garza, Richard -- Baylor College of Medicine
Modafinil and Escitalopram for Cocaine Addiction

De Wit, Harriet -- University of Chicago
Is Ecstasy an Empathogen? Effects of MDMA on Social and Emotional Processing

Deadwyler, Samuel A. -- Wake Forest University Health Sciences
Neuroimaging Correlates of Cocaine Reinforcement for Cognitive Performance

Delgado, Mauricio R. -- Rutgers The State University of New Jersey, Newark
Neural Mechanisms of Avoidance Learning and Active Coping via Emotion Regulation

Donny, Eric Christian -- University of Pittsburgh at Pittsburgh
Polymorphisms Related to Dopamine Receptor Function and Smoking

Dugosh, Karen Leggett -- Treatment Research Institute, Inc. (TRI)
Improving Ethics in Research Development of the Coercion Assessment Scale (CAS)

Dukic, Vanja -- University of Chicago
Translational Approaches to Multilevel Models of Prenatal Exposure to Cigarettes

Dunlap, Eloise -- National Development & Research Institutes
Video Games' Role in Developing Substance Use

Duran, Bonnie M. -- Northwest Indian College
CBPR with Tribal Colleges-Universities: Alcohol Problems-Solutions

Edberg, Jeffrey C. -- University of Alabama at Birmingham
Functional Evaluation of ITGAM SNPs

Edelen, Maria Orlando -- Rand Corporation
Development and Evaluation of a Smoking Module for Promis

Ehringer, Marissa A. -- University of Colorado at Boulder
Nicotinic Receptor Genes & Substance Abuse: Functional Studies of Associated SNPs

Ellinor, Patrick Thomas -- Massachusetts General Hospital
Functional Assessment of the Locus for Atrial Fibrillation on Chromosome 4q25

Evans-Campbell, Teresa A. -- Northwest Indian College
Caring for our Generations: Supporting Native Mothers and their Families

Feingold, Alan J. -- Oregon Social Learning Center, Inc.
Woman Substance Use and Intimate Partner Violence

Fishbein, Diana H. -- Research Triangle Institute
Effects of Yoga on Physiological and Behavioral Precursors of Drug Abuse

Flynn, Patrick M. -- Texas Christian University
Extending Drug Abuse Treatment & Assessment Resources (DATAR5)

Gabuzda, Dana H. -- Dana-Farber Cancer Institute
Systems Biology of Immune Reconstitution in HIV/AIDS

Gahring, Lorise C. -- University of Utah
Mechanisms of TNFa Enhancement of Nicotinic Receptor Upregulation

Gelernter, Joel -- Yale University
Genomewide Association Study of Cocaine Dependence in two Populations

Gelovani, Juri G. -- University of Texas MD Anderson Cancer Center
HDAC Class IIa specific PET radiotracers for PET imaging of CNS

Gerak, Lisa R. -- University of Texas Health Sciences Center, San Antonio
Behavioral Effects of Neuroactive Steroids

Gintzler, Alan R. -- SUNY Downstate Medical Center
Sex-Dependent Tolerance and Withdrawal Mechanisms

Grant, Jon E. -- University of Minnesota Twin Cities
N-Acetyl Cysteine plus Behavioral Therapy for Nicotine Dependent Pathological Gam

Greene, Kathryn L. -- Rutgers the State University of New Jersey, New Brunswick
Active Involvement in Creating High School Substance Use Prevention Messages

Guo, Guang -- University of North Carolina, Chapel Hill
Genetic/Epigenetic Markers, Social Contexts, Lifecourse and Risky Health Behavior

Hall, Sharon M. -- University of California, San Francisco
Maintaining Nonsmoking

Hauser, Kurt Francis -- Virginia Commonwealth University
Fractalkine as a Therapeutic for Opioid Accelerated Neurotoxicity In HIV

Hawrylycz, Michael -- Allen Institute for Brain Science
Co-expression Networks of Addiction-Related Genes in the Mouse and Human Brain

Heintz, Nathaniel -- Rockefeller University
Translational and Epigenetic Profiling of Cell Types Associated with Addiction

Hemby, Scott Edwards -- Wake Forest University Health Sciences
Proteomic Biosignatures of Withdrawal from Cocaine in Rhesus Monkeys

Henry, Loren Keith -- University of North Dakota
Computational and Biochemical Docking of Dopamine Transporter Antagonists

Hoffer, Lee David -- Case Western Reserve University
Researching the Social Dynamics of a Local Methamphetamine Market

Hoffman, Kim -- Oregon Health and Science University
Agency Process Improvement and Client Outcomes

Hohmann, Andrea Grace -- University of Georgia
An Animal Model of Therapeutic Self-Medication for Neuropathic Pain

Holtz, R. Barry -- Intervexion Therapeutics, LLC
Chimeric anti-Methamphetamine Monoclonal Antibody for Treating Stimulant Toxicity

Hooper, Scott L. -- Ohio University Athens
Using Perturbation to Characterize, and Build Models of, Individual Neurons

Hunt, Geoffrey P. -- Scientific Analysis Corporation
Asian American MSM, Club Drugs and Nightlife

Husbands, Stephen M. -- University of Bath
Discovery of New Treatments for Drug Abuse

Hutchison, Kent E. -- The Mind Research Network
Effectiveness of Varenicline: Testing Individual Differences

Jernigan, Terry L. -- University of California, San Diego
Creating a Pediatric Imaging-Genomics Data Resource

Johnson, Eric O. -- Research Triangle Institute
Genome-Wide Association Study of Heroin Abuse: A Multiethnic Study

Kaminski, Norbert E. -- Michigan State University
THC Impairment of CD4/CD8 T Cell-Mediated Host Resistance to HIV and Influenza

Karn, Jonathan -- Case Western Reserve University
Manipulating Epigenetic Control Mechanisms to Control HIV Transcription

Kessler, Paul D. -- Nabi Biopharmaceuticals
Phase III Study of a Nicotine Vaccine for Smoking Cessation

Kiehl, Kent A. -- The Mind Research Network
Socio-Moral Processing in Psychopathy and Substance Abuse

Killen, Joel D. -- Stanford University
Extended Treatment for Smoking Cessation

Knowles, James A. -- University of Southern California
Transcriptional Atlas of Human Brain Development

Kollins, Scott H. -- Duke University
Genetic Basis of Smoking Abstinence, Smoking Reinforcement, and Inhibitory Control

Koob, George F. -- Scripps Research Institute
Neuronal Substrates of Cocaine Reward

Latimer, William W. -- Johns Hopkins University
Adapt US Version of IFCBT-HIVPI to Prevent HIV among Drug Users in South Africa

Latkin, Carl A. -- Johns Hopkins University
Feasibility of Pharmacy-Based HIV Interventions among IDUs: India

Lee, Tong H. -- Duke University
Novel Ondansetron Formulation for Combination Treatment of Psychostimulant Abuse

Lerman, Caryn -- University of Pennsylvania
Nicotine Abstinence-Induced Cognitive Alterations by COMT Genotype

Lerman, Caryn -- University of Pennsylvania
Functional Characterization of OPRM1 A118G in Nicotine Dependence

Lesage, Mark G. -- Minneapolis Medical Research Foundation, Inc.
Determinants of Nicotine Reinforcement Thresholds and Demand Elasticity in Rats

Lester, Henry A. -- California Institute of Technology
Mice with Functional Fluorescent Nicotinic Receptor Subunits

Lever, John Riley -- University of Missouri-Columbia
Development of Anti-Cocaine Medications

Linares, Lourdes O. -- Mount Sinai School of Medicine of NYU
Early Prevention of Substance Use Initiation in Foster Care

Loftis, Jennifer M. -- Oregon Health and Science University
Pre-Clinical Testing of a Novel Immunotherapy [Recombinant T Cell Receptor Ligand]

Maidment, Nigel T. -- University of California, Los Angeles
Peptide Biomarkers of Drug Exposure: From Brain Microdialysate to Plasma

Malison, Robert T. -- Yale University
DBH, D2High and Cocaine Paranoia/Aversion: A [11C]PHNO PET Study

Marcondes, Maria Cecilia Garibaldi -- Scripps Research Institute
Free Radicals and Methamphetamine Abuse

Martinez, Diana M. -- Columbia University Health Sciences
Imaging the Neurochemistry of Negative Reinforcement in Cocaine Abuse

Martinez, Diana M. -- New York State Psychiatric Institute
PET Imaging of the mGluR5 in Cocaine Abuse

Mash, Deborah C. -- University of Miami School of Medicine
CNS Mechanisms in Cocaine-Related Sudden Death

Mayfield, Roy D. -- University of Texas, Austin
Blood and Brain Gene Profiling in Stimulant Self-Administration

Mbilinyi, Lyungai Filela -- University of Washington
Motivating Substance Abusing Batterers To Seek Treatment

McCaul, Mary E. -- Johns Hopkins University
Imaging Varenicline Effects on Nicotine & Dopamine: Gene Modulation

McDonald, Douglas Corry -- Abt Associates, Inc.
Conduct a Nationwide Epidemiological Study of Rx Drug Diversion for Non-Medical Use

McKay, Dennis Brian -- Ohio State University
Novel Lead Molecule Optimization Targeting Nicotinic Receptor Subtypes

Mclean, John Alan -- Vanderbilt University
Elucidation of Leukocyte and Macrophage Biomarker Signatures from Drugs of Abuse

McMahon, Robert J. -- University of Washington
Emergence of Adolescent Substance Use Problems from the Externalizing Spectrum

Medina, Krista Lisdahl -- University of Cincinnati
Effects of SLC6A4, BDNF and Ecstasy Use on Brain Structure in Young Adults

Mello, Nancy K. -- Mc Lean Hospital (Belmont, MA)
Preclinical Evaluation of Medications to Treat Polydrug Addiction

Metrik, Jane -- Brown University
Genetic Variation and Marijuana's Pharmacologic and Cue-Elicted Effects

Milan, David J. -- Massachusetts General Hospital
The Genetic Basis of Novel Loci Influencing Myocardial Repolarization

Mitchell, Suzanne H. -- Oregon Health and Science University
Exercise-Induced Changes in Impulsivity and Cocaine Self-Administration

Mizel, Steven B. -- Wake Forest University Health Sciences
Development of a Flagellin-Cocaine Conjugate Vaccine

Mohlke, Karen L. -- University of North Carolina, Chapel Hill
Identifying Disease-Related Functional Regulatory Variants in Open Chromatin

Morgan, Michael M. -- Washington State University
Psychostimulants Induce Long-Term Changes in Nociception

Morgenstern, Jon -- Morgenstern National Center on Addiction/Substance Abuse
Treating Addiction as a Chronic Illness

Moult, John -- University of Maryland Biotechnology Institute
Mechanisms of Action of SNPs Associated with Common Disease

Mueller, Devin -- University of Wisconsin Milwaukee
Glutamate and Prefrontal Regulation of Cocaine Seeking After Extinction

Mukhin, Alexey G. -- Duke University
Improving the Efficacy of Anti-Nicotine Immunotherapy

Narendran, Rajesh -- University of Pittsburgh at Pittsburgh
PET Imaging of Cortical Dopamine Transmission in Cocaine Addiction

Neubert, John K. -- University of Florida
Placebos as Insights into Intersections of Pain and Reward in a Preclinical Model

Nikulina, Ella M. -- University of Arizona
Social Stress and Psychostimulant Cross-Sensitization

Nyamathi, Adeline M. -- University of California, Los Angeles
Health Promotion Coaching/Vaccine for Homeless Parolees

Obasi, Ezemenari M. -- University of Georgia
Stress and Drug Use Vulnerability in Rural African Americans

O'Brien, Richard M. -- Vanderbilt University
Characterization of Effects of G6PC2 Gene Variants on Transcription and Splicing

Ogawa, Masaaki -- University of Maryland, Baltimore
Neural Mechanisms of Associative Learning from Negative Reward Prediction Errors

Ophoff, Roel A. -- University of California, Los Angeles
Epigenetics and Disease: The Role of DNA Methylation in Schizophrenia Susceptibility

Palmer, Abraham A. -- University of Chicago
Weighted Genome-Wide Association Study of Amphetamine Sensitivity in Humans

Pan, Zhizhong Z. -- University of Texas MD Anderson Cancer Center
Synaptic Mechanisms for Interactions of Chronic Pain and Opioid Addiction

Paulson, Pamela Elizabeth -- University of Michigan at Ann Arbor
Neuroimaging of CNS Interactions in Addiction, Chronic Pain and Analgesia

Pavlopoulos, Spiro -- University of Connecticut, Storrs
Methods for the Development of Arrestin2 Inhibitors

Pereira Arboleya, Mariana -- Rutgers The State University of New Jersey, Newark
Cocaine Disruption of Maternal Motivation: Preference for Pups Vs. Cocaine

Perkins, Kenneth Alan -- University of Pittsburgh at Pittsburgh
Behavioral Genetics of Mood-Induced Smoking

Perron, Brian E. -- University of Michigan at Ann Arbor
Symptoms and Structure of Inhalant Use Disorders

Petry, Nancy M. -- University of Connecticut School of Medicine/Dentistry
Reinforcing Exercise in Cocaine Abusers

Phillips, Paul E. M. -- University of Washington
Spatiotemporal Dynamics of Striatal Dopamine Release in Reinforcement Learning

Piomelli, Daniele -- University of California, Irvine
Lipid Biosignatures of Drug Addiction

Pisano, M. Michele -- University of Louisville
Developmental Cigarette Smoke Exposure: Biomarkers of Neurotoxicity

Rangel, Antonio -- California Institute of Technology
A Neuroimaging Test of the Reenforcement Learning Dysregulation Model of Addiction

Rawls, Scott M. -- Temple University
Beta-Lactam Chemical Probes for GLT-1 Transporter-Related Pathologies

Rawson, Richard A. -- University of California, Los Angeles
Aerobic Exercise to Improve Outcomes of Treatment for Methamphetamine Dependence

Rodriguez Zas, Sandra L. -- University of Illinois, Urbana-Champaign
Integration of Resources and Studies to Elucidate Neuropeptide Signaling

Sacks, Stanley -- National Development & Research Institutes
Computerized Psychosocial Treatment for Offenders with Substance Use Disorders

Schnitzler, Gavin R. -- Tufts Medical Center
Does The Extreme Variability Of Methadone Metabolism Have An Epigenetic Cause?

Schulman, Howard -- PPD, Inc.
Proteomic Biosignatures of Chronic Drug Exposure

Schwartz, Robert P. -- Friends Research Institute, Inc.
SBIRT in New Mexico

Schweizer, Felix E. -- University of California Los Angeles
Indicators of Early Neurodegeneration: Gene-Toxin Interactions at the Syanpse

Sekaly, Rafick-Pierre -- Oregon Health and Science University
Novel Concepts for the Eradication of HIV

Shaboltas, Alla V. -- Biomedical Center
International Feasibility Study of Pharmacy-Based HIV Prevention: St. Petersburg

Sharp, Burt M. -- University of Tennessee Health Sciences Center
Neuron-Specific Candidate Gene Expression and Adolescent Vulnerability to Smoking

Sigmon, Stacey C. -- University of Vermont & State Agricultural College
Individual Differences in Stimulant Reinforcement as a Function Of DRD2 Allele

Smith, Emilie P. -- Pennsylvania State University-University Park
Prevention and Promotion with Youth in Community-Based Afterschool Programs

Smith, Mark A. -- Davidson College
Physical Activity and Substance Abuse

Smits, Jasper -- Southern Methodist University
Exercise Intervention for Smoking

Sofuoglu, Mehmet -- Yale University
Sensitivity to Intravenous Nicotine: Genetic Moderators

Sombers, Leslie A. -- North Carolina State University, Raleigh
Characterization of Cholinergic Modulation of Dopamine Neurotransmission

Soreca, Isabella -- University of Pittsburgh at Pittsburgh
The Effect of Exercise on Acute Nicotine Withdrawal: Human Study

Spoth, Richard L. -- Iowa State University
Rural Youth and Family Competencies Building Projects

Spoth, Richard L. -- Iowa State University
Toward a PROSPER State Partnership Network: Building Infrastructure and Capacity

Stacy, Alan W. -- Claremont Graduate University
Teenage Stimulant Use: Neurally Plausible Spontaneous and Protective Processes

Stella, Nephi -- University of Washington
Role of ABHD6 in 2-AG Signaling

Stinchcomb, Audra L. -- Alltranz, Inc.
Transdermal Cannabinoid Prodrug Treatment for Cannabis Withdrawal and Dependence

Stitzel, Jerry A. -- University of Colorado at Boulder
Function of the CHRNA5 D398N SNP: Implications for Addiction and Lung Cancer Risk

Stormshak, Elizabeth A. -- University of Oregon
An Internet Infrastructure for Quality Implementation of the Family Check-Up

Sumikawa, Katumi -- University of California, Irvine
Maternal Nicotine Exposure and Development of Hippocampal Circuits

Swerdlow, Neal R. -- University of California, San Diego
Genetics of Individual Differences in Amphetamine Effects on Startle Gating

Szapocznik, Jose -- University of Miami School of Medicine
Brief Strategic Family Therapy versus Treatment as Usual: Extended Follow-up

Thomas, David L. -- Johns Hopkins University
Hepatitis C Pathogenesis and the Human Genome

Thomas, Lisa R. -- Northwest Indian College
Native Pathways to Sobriety: Pacific Northwest Oral Life Histories

Toborek, Michal J. -- University of Kentucky
Exercise as a Novel Strategy to Target Methamphetamine-Induced Cerebrovascular

Umbricht, Annie -- Johns Hopkins University
Effect of Zonisamide on Cocaine Reinforcement, Craving and Relapse

Wager, Tor Dessart -- Columbia University New York, Morningside
Learning to Avoid Pain: Computational Mechanisms and Application to Methamphetamine

Warner, Tamara Duckworth -- East Carolina University
Brain Development, Behavior and Cognition in Pre- and Postnatal Cocaine Exposure

Waterhouse, Barry Dale -- Drexel University
Locus Coeruleus Function and Methylphenidate Action

Watson, Dennis Paul -- Loyola University of Chicago
Housing First Model Fidelity and Implications for Substance Abuse Treatment

Weinshenker, David -- Emory University
Effects of Voluntary Exercise on Reinstatement of Cocaine Seeking

Wessling-Resnick, Marianne -- Harvard University (School of Public Health)
HFE: A Genetic Determinant of Olfactory Mn Absorption and Toxicity

Whitesell, Nancy Rumbaugh -- University of Colorado Denver/Health Sciences Center, Denver
Factors Related to Substance Use Development in Young American Indian Adolescents

Wickstrom, Eric -- Thomas Jefferson University
Neuronal mRNA PET Imaging

Williams, Mark L. -- University of Texas Health Sciences Center, Houston
Tanzanian Drug Treatment as AIDS Prevention - Reliability and Validity Study

Winger, Gail D. -- University of Michigan at Ann Arbor
Impulsivity and Demand for Drug in Rhesus Monkeys

Wolgemuth, Debra J. -- Columbia University Health Sciences
Role of Intronic Variants Affecting Splicing in Juvenile Myoclonic Epilepsy

Woods, James H. -- University of Michigan at Ann Arbor
Dopamine D2/D3 Receptors in Compulsive Disorders

Woody, George E. -- University of Pennsylvania
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone

Wu, Nancy S. -- University of California, Los Angeles
Real-time Assessment for Adolescents' Substance Use Behaviors

Xiao, Guanghua -- University of Texas SouthWest Medical Center/Dallas
Secondary Data Analyses for Substance Abuse Research

Xiao, Xinshu Grace -- University of California, Los Angeles
Functions of Genetic Variants in Alternative Splicing and Biological Networks

Yadid, Gal -- Bar-Ilan University
Possible Treatment of Cocaine Craving and Relapse by Memory Erasure

Yin, Hang -- University of Colorado at Boulder
Probing Opioid-Induced Glial Activation with Peptide Antagonists

Youngentob, Steven L. -- Upstate Medical University
Fetal Nicotine Exposure and Chemosensory Plasticity

Zaveri, Nurulain T. -- Astraea Therapeutics, LLC
Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse Therapy

Zubieta, Jon-Kar -- University of Michigan at Ann Arbor
Interaction of Smoking and Chronic Pain at Neurochemical and Phenotypic Levels


Index

Research Findings

Program Activities

Extramural Policy and Review Activities

Congressional Affairs

International Activities

Meetings and Conferences

Media and Education Activities

Planned Meetings

Publications

Staff Highlights

Grantee Honors



Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal